Obesity and risk of the less commonly diagnosed subtypes of breast cancer

European Journal of Surgical Oncology

Volumn 35, Issue 9, 2009, Pages 928-935

  Stark, A ^a,b,c   Schultz, D ^a   Kapke, A ^a   Nadkarni, P ^b   Burke, M ^a   Linden, M ^a   Raju, U ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b GEISINGER HEALTH SYSTEM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Body mass index; Breast cancer epidemiologic risk factors; Breast cancer subtype; Epidermal growth factor; Estrogen receptor; HER 2 neu; Progesterone receptor

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIFESTYLE; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR;

BODY MASS INDEX; BREAST NEOPLASMS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OBESITY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 68249115348     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.11.009     Document Type: Article

References (27)

1. Althuis M.D., Fergenbaum J.H., Carcia-Closas M., Brinton L.A., Madigan M.P., and Sherman M.E. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13 (2004) 1558-1568
2. McPherson K., Steel C.M., and Dixon J.M. Breast cancer-epidemiology, risk factors and genetics. BMJ 321 (2000) 624-628
3. Tehard B., Clavel-Chapelon F., and The E3N group. Several anthropometric measurements and breast cancer risk: results of the E3N cohort study. Int J Obes 30 (2006) 156-163
4. Verla-Tebit E., and Chang-Claude J. Anthropometric factors and the risk of pre-menopausal breast cancer in Germany. Eur J Cancer Prev 14 (2005) 419-426
5. Yang X.R., Sherman M.E., Rimm D.L., et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16 (2007) 439-443
6. Millikan R.C., Newman B., Tse C.K., et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007)
7. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295 (2006) 2492-2502
8. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes and obesity related health risk factors. JAMA 289 (2003) 76-79
9. Newman L.A., Bunner S., Carolin K., et al. Ethnicity related differences in the survival of the young breast carcinoma patients. Cancer 95 (2002) 21-27
10. Fisher E.R., Anderson S., Dean S., et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 103 (2004) 164-173
11. Allred D.C., Harvey J.M., Berardo M., and Clarke G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11 (1998) 155-168
12. Wang S., Saboorian M.H., Frenkel E., Hynan L., Gokaslan S., and Ashfaq R. Laboratory assessment HER-2/neu protein and oncogene in breast cancer: comparison of immunohistochemistry assay with fluorescent in situ hybridization assay. J Clin Pathol 53 (2000) 374-381
13. Nielson T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
14. Sorelie T., Perou C.M., Tibshirania R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 (2001) 10869-10874
15. Livasy C.A., Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19 (2006) 264-271
16. Hosmer D., and Lemeshow S. Applied logistic regression. 2nd ed. (1997), John Wiley & Sons, New York (NY)
17. Jones C., Nonni A.V., Fulford L., et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 85 (2001) 422-427
18. van de Rijn M., Perou C.M., Tibshirani R., et al. Expression of cytokeratin 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161 (2002) 1991-1996
19. Tamimi R.M., Byrne G., Colditz G.A., and Hankinson S.E. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 99 (2007) 1178-1187
20. Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in health postmenopausal women. JAMA 288 (2002) 321-333
21. Hersh A., Stefanick M., and Stafford R. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291 (2004) 253
22. Kerlikowske K., Miglioretti D.L., Buist D.S.M., Walker R., and Carney P.A. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. JNCI 99 (2007) 1-5
23. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Human Metab Res 35 (2003) 694-704
24. Friedenreich C.M. Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 10 (2001) 15-32
25. Sprague B.L., Trentham-Dietz A., Egan K.M., Titus-Ernstoff L., Hampton J.M., and Newcomb P.A. Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. Am J Epidemiol 168 (2008) 404-412
26. Anders C.K., Hsu D.S., Braodwater G., et al. Young age at diagnosis with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26 (2008) 3324-3330
27. Gelber S.A.S., Castiglione-Gertsch M., Gelber R.D., et al. Is chemotherapy alone adequate for young women with oestrogen receptor positive breast cancer?. The Lancet 355 (2000) 1869-1874